Impact of time-varying treatment exposures on the risk of venous thromboembolism in multiple myeloma

Joshua D. Brown; Val R. Adams; Daniela C. Moga

doi:10.3390/healthcare4040093

Impact of time-varying treatment exposures on the risk of venous thromboembolism in multiple myeloma

Joshua D. Brown
, Val R. Adams
, Daniela C. Moga

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Multiple myeloma (MM) has one of the highest risks of venous thromboembolism (VTE) of all cancers due to pathologic changes and treatment-related exposures. This study assessed the one-year incidence of VTE in newly diagnosed MM and to determine the baseline and time-varying treatment-related factors associated with VTE risk in a U.S.-based cohort. MM patients were identified and age, gender, and baseline comorbidities were determined. Treatment-related exposures included thalidomide derivatives (IMIDs), proteasome inhibitors, cytotoxic chemotherapy, steroids, erythropoietin-stimulating agents (ESAs), stem cell transplants (SCT), hospitalizations, infection, and central venous catheters (CVC). Multiple statistical models were used including a baseline competing risks model, a time-varying exposure Cox proportional hazard (CPH) model, and a case-time-control analysis. The overall incidence of VTE was 107.2 per 1000 person-years with one-half of the VTEs occurring in the first 90 days. The baseline model showed that increasing age, heart failure, and hypertension were associated with one-year incidence of VTE. MM-specific IMID treatment had lower than expected associations with VTE based on prior literature. Instead, exposure to ESAs, SCT, CVC, and infection had higher associations. Based on these results, VTE risk in MM may be less straightforward than considering only chemotherapy exposures, and other treatment-related exposures should be considered to determine patient risk.

Original language	English
Article number	93
Journal	Healthcare (Switzerland)
Volume	4
Issue number	4
DOIs	https://doi.org/10.3390/healthcare4040093
State	Published - Dec 2016

Bibliographical note

Publisher Copyright:
© 2016 by the authors; licensee MDPI, Basel, Switzerland.

Funding

Acknowledgments: Joshua D. Brown and Val R. Adams are supported by a grant from the Hematology/Oncology Pharmacists Association (HOPA). Daniela C. Moga is supported by grant number K12 DA035150 from the National Institutes of Health (NIH), Office of Women’s Health Research and the National Institute on Drug Abuse. The project described was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through grant number UL1TR000117. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Funders	Funder number
Hematology/Oncology Pharmacists Association	K12 DA035150
National Institutes of Health (NIH)
National Institute on Drug Abuse
Office of Research on Women's Health
National Center for Advancing Translational Sciences (NCATS)	UL1TR000117
National Center for Advancing Translational Sciences (NCATS)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Case-time-control study design
Competing risks
Deep vein thrombosis
Multiple myeloma
Venous thromboembolism

ASJC Scopus subject areas

Leadership and Management
Health Policy
Health Informatics
Health Information Management

Access to Document

10.3390/healthcare4040093

Cite this

@article{4ba20138fbd049b3b11223dc67a09abf,

title = "Impact of time-varying treatment exposures on the risk of venous thromboembolism in multiple myeloma",

abstract = "Multiple myeloma (MM) has one of the highest risks of venous thromboembolism (VTE) of all cancers due to pathologic changes and treatment-related exposures. This study assessed the one-year incidence of VTE in newly diagnosed MM and to determine the baseline and time-varying treatment-related factors associated with VTE risk in a U.S.-based cohort. MM patients were identified and age, gender, and baseline comorbidities were determined. Treatment-related exposures included thalidomide derivatives (IMIDs), proteasome inhibitors, cytotoxic chemotherapy, steroids, erythropoietin-stimulating agents (ESAs), stem cell transplants (SCT), hospitalizations, infection, and central venous catheters (CVC). Multiple statistical models were used including a baseline competing risks model, a time-varying exposure Cox proportional hazard (CPH) model, and a case-time-control analysis. The overall incidence of VTE was 107.2 per 1000 person-years with one-half of the VTEs occurring in the first 90 days. The baseline model showed that increasing age, heart failure, and hypertension were associated with one-year incidence of VTE. MM-specific IMID treatment had lower than expected associations with VTE based on prior literature. Instead, exposure to ESAs, SCT, CVC, and infection had higher associations. Based on these results, VTE risk in MM may be less straightforward than considering only chemotherapy exposures, and other treatment-related exposures should be considered to determine patient risk.",

keywords = "Case-time-control study design, Competing risks, Deep vein thrombosis, Multiple myeloma, Venous thromboembolism",

author = "Brown, \{Joshua D.\} and Adams, \{Val R.\} and Moga, \{Daniela C.\}",

note = "Publisher Copyright: {\textcopyright} 2016 by the authors; licensee MDPI, Basel, Switzerland.",

year = "2016",

month = dec,

doi = "10.3390/healthcare4040093",

language = "English",

volume = "4",

number = "4",

}

TY - JOUR

T1 - Impact of time-varying treatment exposures on the risk of venous thromboembolism in multiple myeloma

AU - Brown, Joshua D.

AU - Adams, Val R.

AU - Moga, Daniela C.

PY - 2016/12

Y1 - 2016/12

N2 - Multiple myeloma (MM) has one of the highest risks of venous thromboembolism (VTE) of all cancers due to pathologic changes and treatment-related exposures. This study assessed the one-year incidence of VTE in newly diagnosed MM and to determine the baseline and time-varying treatment-related factors associated with VTE risk in a U.S.-based cohort. MM patients were identified and age, gender, and baseline comorbidities were determined. Treatment-related exposures included thalidomide derivatives (IMIDs), proteasome inhibitors, cytotoxic chemotherapy, steroids, erythropoietin-stimulating agents (ESAs), stem cell transplants (SCT), hospitalizations, infection, and central venous catheters (CVC). Multiple statistical models were used including a baseline competing risks model, a time-varying exposure Cox proportional hazard (CPH) model, and a case-time-control analysis. The overall incidence of VTE was 107.2 per 1000 person-years with one-half of the VTEs occurring in the first 90 days. The baseline model showed that increasing age, heart failure, and hypertension were associated with one-year incidence of VTE. MM-specific IMID treatment had lower than expected associations with VTE based on prior literature. Instead, exposure to ESAs, SCT, CVC, and infection had higher associations. Based on these results, VTE risk in MM may be less straightforward than considering only chemotherapy exposures, and other treatment-related exposures should be considered to determine patient risk.

AB - Multiple myeloma (MM) has one of the highest risks of venous thromboembolism (VTE) of all cancers due to pathologic changes and treatment-related exposures. This study assessed the one-year incidence of VTE in newly diagnosed MM and to determine the baseline and time-varying treatment-related factors associated with VTE risk in a U.S.-based cohort. MM patients were identified and age, gender, and baseline comorbidities were determined. Treatment-related exposures included thalidomide derivatives (IMIDs), proteasome inhibitors, cytotoxic chemotherapy, steroids, erythropoietin-stimulating agents (ESAs), stem cell transplants (SCT), hospitalizations, infection, and central venous catheters (CVC). Multiple statistical models were used including a baseline competing risks model, a time-varying exposure Cox proportional hazard (CPH) model, and a case-time-control analysis. The overall incidence of VTE was 107.2 per 1000 person-years with one-half of the VTEs occurring in the first 90 days. The baseline model showed that increasing age, heart failure, and hypertension were associated with one-year incidence of VTE. MM-specific IMID treatment had lower than expected associations with VTE based on prior literature. Instead, exposure to ESAs, SCT, CVC, and infection had higher associations. Based on these results, VTE risk in MM may be less straightforward than considering only chemotherapy exposures, and other treatment-related exposures should be considered to determine patient risk.

KW - Case-time-control study design

KW - Competing risks

KW - Deep vein thrombosis

KW - Multiple myeloma

KW - Venous thromboembolism

UR - https://www.scopus.com/pages/publications/85044359740

UR - https://www.scopus.com/pages/publications/85044359740#tab=citedBy

U2 - 10.3390/healthcare4040093

DO - 10.3390/healthcare4040093

M3 - Article

AN - SCOPUS:85044359740

SN - 2227-9032

VL - 4

JO - Healthcare (Switzerland)

JF - Healthcare (Switzerland)

IS - 4

M1 - 93

ER -

Impact of time-varying treatment exposures on the risk of venous thromboembolism in multiple myeloma

Abstract

Bibliographical note

Funding

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this